George Alva
Family · Odessa, TXNPI 1639766140
Payments from drug & device makers
Across 137 payments — averaging $25.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$550
- AstraZeneca$517
- Lilly USA, LLC$492
- Harmony Biosciences LLC$434
- Abbott$357
- Pfizer$273
- plus $910 from 18 others
What the payments were for
- Food & beverage$3,30393%
- Education$2006%
- Other$301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 29 | $550 |
| AstraZeneca | 16 | $517 |
| Lilly USA, LLC | 25 | $492 |
| Harmony Biosciences LLC | 10 | $434 |
| Abbott | 3 | $357 |
| Pfizer | 15 | $273 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $146 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $145 |
| Novo Nordisk | 7 | $138 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $60 |
| Axsome Therapeutics, Inc. | 3 | $51 |
| Antares Pharma, Inc. | 2 | $45 |
| Medtronic | 2 | $42 |
| Jazz Pharmaceuticals Inc. | 1 | $38 |
| Edwards Lifesciences | 1 | $37 |
| Biohaven Pharmaceuticals, Inc. | 2 | $31 |
| GSK | 1 | $30 |
| Boehringer Ingelheim | 1 | $30 |
| Corium, LLC | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $22 |
| Tris Pharma Inc | 1 | $21 |
| Halozyme Inc | 1 | $19 |
| Genentech USA, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FreeStyle Libre$177
- FREESTYLE LIBRE 3$150
- BREZTRI$128
How this compares
$3,533 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 70 | $85,443 |
| MounjaroTirzepatide | 18 | $23,797 |
| QuliptaAtogepant | 12 | $14,277 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 13 | $1,277 |
| Testosterone Cypionate | 14 | $960 |
| Gabapentin | 17 | $430 |
| Clonazepam | 39 | $370 |
| Pantoprazole Sodium | 33 | $366 |
| Buspirone Hcl | 17 | $331 |
| Ondansetron OdtOndansetron | 19 | $327 |
| Cyclobenzaprine Hcl | 21 | $279 |
| Tizanidine Hcl | 13 | $174 |
| Zolpidem Tartrate | 28 | $131 |
| Tamsulosin Hcl | 17 | $127 |
| Alprazolam | 27 | $99 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $138 | $85,44370 claims |
| Lilly USA, LLCMounjaro | $492 | $23,79718 claims |
| AbbVieQulipta | $550 | $14,27712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.
Other family in Odessa
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.